Inhibrx Biosciences, Inc. (INBX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.37B USD. 52-week range 28.16 to 155.29 USD. Data as of 2026-10-09.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell ...